<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621488</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL17_0215</org_study_id>
    <nct_id>NCT03621488</nct_id>
  </id_info>
  <brief_title>Behavioral Self-activation and Virtual Reality in Depression</brief_title>
  <acronym>DEPREVACT</acronym>
  <official_title>Randomized Controlled Study of the Efficacy of Behavioral Self-Activation Through Virtual Reality in the Treatment of Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>C2care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression is a major handicap in daily life and is often treated by behavioral activation&#xD;
      (CA), including the Brief Behavioral Activation Treatment for Depression (BATD).The CA&#xD;
      principle is to set up activities, in keeping with the values of the individual. Other tools&#xD;
      associated with the CA deserve to be explored as virtual reality (VR), which offers scenarios&#xD;
      and sensations similar to real life and a sense of life. in a safe and controlled&#xD;
      environment, with the support of the therapist.The main objective is to compare the&#xD;
      effectiveness of the program &quot;BATD with RV&quot; versus &quot;BATD without RV&quot; on the intensity of the&#xD;
      depressive symptomatology and CA in everyday life.&#xD;
&#xD;
      Methodology: This is a randomized, blinded study. Inclusion criteria are: 18 to 70 years old;&#xD;
      unipolar depression diagnosis; Showing a score of ≥ 17 on the BDI-II. 80 subjects will be&#xD;
      recruited over 24 months and randomized into 2 groups: 1) intervention group program BATD in&#xD;
      VR; 2) BATD program intervention group without RV, lasting 45 minutes.&#xD;
&#xD;
      Judgment Criteria: The effectiveness of the intervention will be evaluated by the BDI-II&#xD;
      scale and the Behavioral Activation for Depression Scale (BADS).&#xD;
&#xD;
      Outcomes: A new management of depression (AC with RV) to improve the quality of life of the&#xD;
      patient; proof of its effectiveness; a generalization of this care; and recognition of its&#xD;
      effectiveness in the scientific community.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of depression</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>Beck Depression Inventory version II (BDI-II; depression) ; decrease BDI-II score between 0 and 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of depressive symptoms</measure>
    <time_frame>0, 3 and 6 months</time_frame>
    <description>Inventory of Depressive Symptomatology by the clinician (IDS-C) ; decrease IDS-C score between 0 and 3 months ; and between 0 and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of depression</measure>
    <time_frame>0 and 3 months</time_frame>
    <description>Beck Depression Inventory version II (BDI-II; depression) ; decrease BDI-II score between 0 and 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life quality</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>The Short Form (36) Health Survey (SF36) ; increase quality of life in the end of the treatment and three months later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical fatigue</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Multidimensional Fatigue Inventory (physical fatigue); Reduce the level of physical fatigue, in the end of the treatment and three months later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of activities</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Number of spontaneous activities performed during the week. Increase the number of activites in daily life in the end of the treatment and three months later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hopelessness</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Beck Hopelessness scale (feelings about the future, loss of motivation, and expectations); increase hope, in the end of the treatment and three months later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic alliance</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 weeks; 13 and 6 months</time_frame>
    <description>Attendance at sessions and visits during all the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Efficacy of Behavioral Self-Activation with virtual reality</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 individual sessions of the Brief Behavioral Activation Treatment for Depression (BATD) program, lasting one hour, at the start of treatment, then half an hour thereafter, once a week&#xD;
+ virtual reality activities of the session 4 to 9 lasting half an hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efficacy of Behavioral Self-Activation without virtual reality</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>10 individual sessions of the Brief Behavioral Activation Treatment for Depression (BATD) program, lasting one hour, at the start of treatment, then half an hour thereafter, once a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Efficacy of Behavioral Self-Activation with virtual reality</intervention_name>
    <description>Efficacy of Behavioral Self-Activation with virtual reality</description>
    <arm_group_label>Efficacy of Behavioral Self-Activation with virtual reality</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Efficacy of Behavioral Self-Activation without virtual reality</intervention_name>
    <description>Efficacy of Behavioral Self-Activation without virtual reality</description>
    <arm_group_label>Efficacy of Behavioral Self-Activation without virtual reality</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged 18 to 70,&#xD;
&#xD;
          2. Having a diagnosis of unipolar depressive disorder characterized (diagnostic criteria&#xD;
             of depression of DSM-V),&#xD;
&#xD;
          3. Primary depression and not secondary to another disorder (eg social phobia, OCD,&#xD;
             severe personality disorder, ASD, TCA, ect.)&#xD;
&#xD;
          4. Showing a score greater than or equal to 17 points on the IDB-II,&#xD;
&#xD;
          5. Followed by a psychiatrist from the University Hospital of Montpellier or a liberal,&#xD;
&#xD;
          6. Can read, understand and speak French,&#xD;
&#xD;
          7. To be affiliated or beneficiary of a social security scheme.&#xD;
&#xD;
          8. Collection of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (1) History of head trauma or recent central neurological conditions only (2) Current&#xD;
        treatment by seismotherapy or rTMS or CBT. (3) Exclusion from all substance-related&#xD;
        disorders except tobacco-related disorder (DSM-V)&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine CAPDEVIELLE, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospitals of Montpellier, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre DE CONNOR</last_name>
    <phone>+334.67.33.24.26</phone>
    <email>a-deconnor@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jérôme ATTAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine CAPDEVIELLE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Behavioral Activation</keyword>
  <keyword>Virtual reality</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

